TIRZEPATIDE

Information current as at: 1 June 2026

The pharmaceutical company has advised that it is not proceeding in the PBS listing process at this time. The process for listing this medicine has ceased.


Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Mounjaro® Mounjaro® KwikPen®
Form and strength:
Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:
ELI LILLY AUSTRALIA PTY LTD
Condition/indication:
(therapeutic use)
  • Type 2 diabetes mellitus
Listing requested:
Please see PSD for more information
Funding program:
Please see PSD for more information
Request authority level:
Please see PSD for more information
PBAC Submission type:
New PBS listing (Matters arising/Matters outstanding)
Comment:
--
Other PBAC consideration:

Progress Details

Submission received for:
March 2026 PBAC meeting
Opportunity for consumer comment:
Open 02/04/2025 and close 28/05/2025 (see PBS Website)
PBAC meeting:
Held on 11/03/2026
PBAC outcome published:
Recommended (see PBAC Outcomes)
Notice of intent submitted:
Awaiting lodgement from pharmaceutical company
Lodgement of required documentation:
Not applicable
Agreement to listing arrangements:
Not applicable
Government processes:
Not applicable
Medicine listed on the PBS:
Not applicable
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Public Summary Document:
Not yet available
Case ID
1251
Page last updated
30 April 2026
Return to the Medicine Status Listing
v.9.19